TriangleNCT00719849 · OUTCOME
Probability of Survival at 1 Year
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- survival probability
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 1 year post transplant
What was measured
Kaplan-Meier estimate of the probability of survival at 1 year
Groups in this outcome
Cyclophosphamide/Fludarabine/TBI
Subjects with hematological malignancies with prior autologous transplant, \>2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months, OR subjects with refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. * Cyclophosphamide 50 mg/Kg Day -6 * Fludarabine 40mg/m2 Days -6 to -2 * TBI 200 cGy Day -1 Immune suppression: begin Day -3 cyclosporine and mycophenolate mofetil
Cyclophosphamide/Fludarabine/TBI/ATG
Subjects with hematological malignancies with prior autologous transplant \>12 mos or \<1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months. * Cyclophosphamide 50 mg/Kg Day -6 * Fludarabine 40mg/m2 Days -6 to -2 * TBI 200 cGy Day -1 * Equine ATG 30mg/Kg Days -6 to -4 Immune suppression: begin Day -3 cyclosporine and mycophenolate mofetil
| Group | Source count |
|---|---|
| Cyclophosphamide/Fludarabine/TBI | 4 |
| Cyclophosphamide/Fludarabine/TBI/ATG | 8 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cyclophosphamide/Fludarabine/TBI | 0.25 | Not reported | 0.046 | 1.000 | Not reported |
| Cyclophosphamide/Fludarabine/TBI/ATG | 0.50 | Not reported | 0.25 | 1.00 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.046
- upper Limit
- 1.000
- value
- 0.25
- group Id
- OG001
- lower Limit
- 0.25
- upper Limit
- 1.00
- value
- 0.50
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 8
- units
- Participants
- description
- Kaplan-Meier estimate of the probability of survival at 1 year
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Subjects with hematological malignancies with prior autologous transplant, \>2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months, OR subjects with refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. * Cyclophosphamide 50 mg/Kg Day -6 * Fludarabine 40mg/m2 Days -6 to -2 * TBI 200 cGy Day -1 Immune suppression: begin Day -3 cyclosporine and mycophenolate mofetil
- id
- OG000
- title
- Cyclophosphamide/Fludarabine/TBI
- description
- Subjects with hematological malignancies with prior autologous transplant \>12 mos or \<1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months. * Cyclophosphamide 50 mg/Kg Day -6 * Fludarabine 40mg/m2 Days -6 to -2 * TBI 200 cGy Day -1 * Equine ATG 30mg/Kg Days -6 to -4 Immune suppression: begin Day -3 cyclosporine and mycophenolate mofetil
- id
- OG001
- title
- Cyclophosphamide/Fludarabine/TBI/ATG
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 1 year post transplant
- title
- Probability of Survival at 1 Year
- type
- PRIMARY
- unit Of Measure
- survival probability
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice